OA13.04 Chromosomal Rearrangements and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors
Journal of Thoracic Oncology(2021)
摘要
Immunotherapy has emerged as a frontline treatment option for malignant pleural mesothelioma (MPM) with the recent approval of the combination of the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab. Whereas tumors with high mutation burdens are typically responsive to immunotherapy, MPM reportedly has a very low mutation burden, which is inconsistent with other tumors related to carcinogen exposures. We previously demonstrated that chromosomal rearrangements are common and have neoantigenic potential in MPM.
更多查看译文
关键词
chromosomal rearrangements, Immune checkpoint inhibitors, antigen presentation
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要